Caprock Group LLC Invests $206,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Caprock Group LLC bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,674 shares of the specialty pharmaceutical company’s stock, valued at approximately $206,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Creative Planning raised its position in Jazz Pharmaceuticals by 21.7% during the second quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock worth $408,000 after acquiring an additional 680 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $213,000. SG Americas Securities LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $752,000. GAMMA Investing LLC lifted its stake in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 121 shares during the last quarter. Finally, Wedmont Private Capital grew its holdings in Jazz Pharmaceuticals by 11.4% during the third quarter. Wedmont Private Capital now owns 4,972 shares of the specialty pharmaceutical company’s stock worth $540,000 after purchasing an additional 507 shares during the period. Institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. TD Cowen dropped their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $177.00.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $120.29 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The company’s 50 day moving average price is $122.55 and its two-hundred day moving average price is $116.34. The firm has a market cap of $7.27 billion, a PE ratio of 16.94, a PEG ratio of 0.90 and a beta of 0.56.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 5,053 shares of company stock worth $617,442 in the last 90 days. Company insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.